Physician profile
Kurt Bormann
NPI 1962615054
$202,927.42
in general payments reported to CMS, 2019-2025
12 companies · $28K in 2025
The $28K reported for 2025 was more than what 93% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35K · 2020: $40K · 2021: $24K · 2022: $26K · 2023: $22K · 2024: $29K · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $43K · Travel and Lodging: $18K · Consulting Fee: $18K · Food and Beverage: $670.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $42,781.47 |
| Travel and Lodging | $17,646.11 |
| Consulting Fee | $17,500.00 |
| Food and Beverage | $670.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Limacorporate S.P.A. | $140,362.37 | 2019-2024 | Smr Shoulder, Smr Shoulder System, Prima |
| Encore Medical, LP | $40,895.36 | 2024-2025 | Djo Surgical |
| Lima USA, INC. | $19,475.27 | 2019-2023 | Smr Shoulder |
| Elite Orthopedics, LLC | $1,204.11 | 2019-2025 | |
| Arthrex, INC. | $436.49 | 2023-2025 | Arthrex |
| Medacta USA, INC. | $253.99 | 2019 | |
| Catalyst Orthoscience | $93.02 | 2020 | |
| Smith+Nephew, INC. | $73.55 | 2020 | |
| Pacira Therapeutics, INC. | $41.85 | 2019-2021 | |
| Organogenesis INC. | $33.92 | 2021-2022 | |
| Hospira, INC. | $31.98 | 2023-2024 | |
| Vertex Pharmaceuticals Incorporated | $25.51 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kurt Bormann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.